Concepedia

Cory Hubler

CH

Statistics

Publications

3

Citations

56

H-Index

3

Active since

2020

Affiliations

JMI Laboratories(Current)

Cory Hubler is an author at JMI Laboratories specializing in beta-lactamase inhibitor resistance, beta-lactam resistance, and beta-lactamase inhibitors.

ORCID

Publications per year

2020–2024

3

Publications

3

Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values

Mariana Castanheira, Timothy B Doyle, Cory Hubler et al. · International Journal of Antimicrobial Agents · 2020 · 31 citations

, , +16

Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and Pseudomonas aeruginosa from Intensive Care Unit and Non-Intensive Care Unit Patients

Hélio S. Sader, Rodrigo E. Mendes, John H. Kimbrough et al. · Antibiotics · 2024 · 13 citations · Full text

, , +16

The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/β-lactamase inhibitor combinations

Mariana Castanheira, Timothy B Doyle, Cory Hubler et al. · Journal of Global Antimicrobial Resistance · 2022 · 12 citations · Full text

, , +17

1–3 of 3